Post-Registration Changes in Nigeria: Notification, Approval and Labelling under Article 6

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Nigeria writes post-registration changes into four progressively stricter obligations (Article 6):

  • Article 6(1): without notifying NAFDAC, the registration certificate holder must not implement any change;
  • Article 6(2): any change that may affect the quality of the device requires prior approval;
  • Article 6(3): the application must describe the proposed change;
  • Article 6(4): the holder must not distribute the device until the change has been evaluated and approved and the labelling has been revised accordingly.

In one sentence: every change must be notified; changes that may affect quality must be approved first; once approved, the labelling must be revised; and only after the labelling is revised may the device be sold. This sequencing is not administrative decoration. Each step creates a record, each record feeds the renewal dossier, and skipping any step converts a routine engineering decision into a regulatory violation with product-withdrawal consequences.

2. Legal basis

RegulationReference numberPublication dateProvisions
NAFDAC Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations, 2024S.I. No. 42 of 202416 October 2024Articles 6(1)–(4) (post-registration changes), Article 8(1)(b) (contravention of conditions as a suspension ground), Articles 16–27 (labelling)
NAFDAC Medical Devices GMP Guidelines 2024DER-GDL-025-00Effective 11 November 2024§12.2 (labelling changes and records), §11.7 (CAPA)
NAFDAC Guidelines for Registration of Medical Devices Including In Vitro Diagnostics (IVDs) and Related ProductsVBM-R&RA-GDL-001-01Effective 10 April 2025§11.6 (automatic closure after 90 days), §11.8 (clock stop for compliance directives)
NAFDAC Medical Devices, including In-vitro Diagnostics and Related Products Regulations, 2025 (draft)None (draft, not gazetted)Published 23 July 2025§40 (post-registration changes, draft)

3. Expert insights

Insight one: Article 6(1) is all-coverage notification — there is no exemption list.

The Regulations provide no list of minor changes that may be exempted. The wording of Article 6(1) is that any change must not be implemented without notification. This differs from the EU MDR approach of change classification combined with changes that need only be notified: Nigeria has written the rule more conservatively. The practical recommendation is to make notification the default action, rather than first debating whether a change counts as major. Classification can still be performed internally for prioritisation, but it should never be used to suppress a notification that the law plainly requires.

Insight two: the trigger in Article 6(2) is possible impact on quality, not risk class.

The trigger condition in Article 6(2) is that the change may affect the quality of the device. This determination requires a technical argument based on the change’s impact on design, materials, processes, sterilisation, shelf life and software, not on how significant the change looks on paper. For example, switching to a second-source packaging material appears minor, but if it affects the sterile barrier, it falls squarely within Article 6(2). A documented impact assessment is what converts this judgement from an opinion into evidence.

Insight three: Article 6(4) is a distribution ban — the hardest sentence in the Article.

Article 6(4) uses the words shall not distribute — until the impact of the change has been evaluated and approved and the labelling has been revised accordingly, the holder must not distribute. The two conditions are cumulative: approval obtained but labelling unrevised means no sales; labelling revised but approval not granted also means no sales. Warehouses and distributors should be told explicitly that release-for-supply is blocked until both gates are cleared, because a single shipment made in the gap between the two gates is already a violation.

Insight four: change management connects to Article 8(1)(b) — contravening conditions can lead to suspension.

Article 8(1)(b): where the conditions on which the registration was granted are contravened, this constitutes a ground for suspension or cancellation of the registration. In other words, the consequence of implementing a change without approval is not merely a retrospective application; it can directly lead to suspension of the certificate and an order to withdraw the product from circulation (Article 8(2)). The commercial value of the stock in the channel is then exposed on top of the regulatory sanction.

Insight five: the 2025 draft elevates post-registration changes into a standalone §40, signalling institutionalisation.

Part 4 of the 2025 draft contains §40 Post-registration changes. The draft is not yet gazetted, but it shows that Nigeria is refining change management into a standalone provision. Until then, the four paragraphs of Article 6 continue to apply. The direction of travel is nonetheless clear: more granular change categories, and likely more prescribed documentation, once the draft becomes law.

4. Practical recommendations

  1. Establish a change-grading SOP, but make notification the default action and do not apply exemptions on your own initiative.
  2. Use possible impact on quality as the technical test, issue a written assessment report and retain it on file.
  3. The change application must describe the proposed change (Article 6(3)); a three-part format of before-and-after comparison table, impact assessment and verification data is recommended.
  4. Make labelling revision the final gate of the change loop; no release without it (Article 6(4)).
  5. Manage changes in linkage with compliance directives: a compliance directive stops the clock (§11.8), and 90 days without a response leads to automatic closure of the application (§11.6).
  6. Track the gazettal progress of draft §40 of 2025 and prepare finer change-classification documentation in advance.

5. Verification checklist

  • □ A change notification SOP has been established covering all types of changes (Article 6(1)).
  • □ The technical assessment of whether quality may be affected has been completed and filed (Article 6(2)).
  • □ The change application describes the proposed change with a before-and-after comparison attached (Article 6(3)).
  • □ Distribution is released only after confirming that both approval and labelling revision conditions are met (Article 6(4)).
  • □ Labelling change records are retained under GMP §12.2.
  • □ A change register has been established and is linked to the renewal self-check list.

Regulatory information verified as of 29 October 2026. All citations have been checked against the official NAFDAC Regulations text (S.I. No. 42 of 2024, Articles 6(1)–(4), 8(1)(b), 16–27), the GMP Guidelines (DER-GDL-025-00 §11.7, §12.2) and VBM-R&RA-GDL-001-01 (§11.6, §11.8); §40 of the 2025 draft was published on 23 July 2025 and is not yet gazetted, and is referenced only as an indication of regulatory direction.

  • Local resources in Nigeria: GRZAN can coordinate locally licensed importer and authorised representative resources, covering NAPAMS electronic submission, dossier screening permit coordination, import permits, sample delivery and laboratory analysis support.
  • Service capabilities: classification determination, registration pathway selection, technical documentation (IMDRF ToC), CMFS and legalisation, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal.
  • Contact: hito.lin@grzan.cn; website www.grzan.cn; email info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail